DIGAMI-2 TRIAL |
| Problem |
DM in acute MI |
| Format |
Double-blinded multi-center RCT |
| Treatment |
Insulin infusion then either insulin OR standard treatment |
| Control |
Routine DM therapy throughout |
| Population |
1,253 patients |
| Inclusion criteria |
Patients with established type 2 diabetes or an admission blood glucose >11.0 mmol/L, admitted to participating coronary care units, were eligible for inclusion according to the following criteria: suspect acute myocardial infarction due to symptoms (chest pain >15 min during the preceding 24 h) and/or recent ECG signs (new Q-waves and/or ST-segment deviations in two or more leads). |
| Exclusion criteria |
Exclusion criteria were inability to cope with insulin treatment or to receive information on the study; residence outside the hospital catchment area; participation in other studies, or previous participation in DIGAMI 2. The study conformed to good clinical practice guidelines and followed the recommendations of the Helsinki Declaration. Local ethics review boards approved the protocol. Written informed consent was obtained from all patients prior to enrolment. |
| Follow-up |
Median 2.1 years |
| Primary endpoint |
Total mortality between continued insulin versus early insulin only |
| Secondary endpoint(s) |
Total mortality between early insulin only and normal local management |
| Details |
. |
| Brief summary: |
Longer-term insulin shows no advantage, but glucose levels predict mortality well |
Subscribe: Latest / All - Designed by Dr James P Howard (Google+)